Pancreatic Cancer Research

ResearcherUniversity of MichiganActive in the last 2 years

Samantha B. Kemp

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-1505-4015; OpenAlex author ID A5058464154; NIH RePORTER profile ID 15119776. Sources: OpenAlex.

Their work

Papers
19 (first author 2, last author 0)
Trials
0
Grants
1
Labs led
0
Collaborators
83
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper, 1 grant · 2021: 5 papers · 2022: 1 paper · 2023: 1 paper · 2024: 5 papers · 2025: 5 papers

Papers 19

  1. Primary and metastatic cellular landscapes in human pancreatic cancer. Co-author DOI 10.1016/j.isci.2025.113012↗
  2. Human Pancreatic Cancer Single-Cell Atlas Reveals Association of CXCL10+ Fibroblasts and Basal Subtype Tumor Cells. First author DOI 10.1158/1078-0432.ccr-24-2183↗
  3. Multimetric MRI Captures Early Response and Acquired Resistance of Pancreatic Cancer to KRAS Inhibitor Therapy. Co-author DOI 10.1158/1078-0432.ccr-24-4049↗
  4. T-cell Dependency of Tumor Regressions and Complete Responses with RAS(ON) Multi-selective Inhibition in Preclinical Models of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/2159-8290.cd-24-1475↗
  5. Multidimensional analyses identify genes of high priority for pancreatic cancer research. Co-author DOI 10.1172/jci.insight.174264↗
  6. Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-07379-z↗
  7. Author Correction: Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer. Co-author DOI 10.1038/s41586-024-08084-7↗
  8. Multiplexed Imaging Mass Cytometry Analysis Characterizes the Vascular Niche in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-23-2352↗
  9. KRT17high/CXCL8+ Tumor Cells Display Both Classical and Basal Features and Regulate Myeloid Infiltration in the Pancreatic Cancer Microenvironment. Co-author DOI 10.1158/1078-0432.ccr-23-1421↗
  10. Notch Signaling Regulates Immunosuppressive Tumor-Associated Macrophage Function in Pancreatic Cancer. Co-author DOI 10.1158/2326-6066.cir-23-0037↗
  11. Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer. Co-author DOI 10.1158/2159-8290.cd-22-1066↗
  12. Metabolic requirement for GOT2 in pancreatic cancer depends on environmental context. Co-author DOI 10.7554/elife.73245↗
  13. The Gustatory Sensory G-Protein GNAT3 Suppresses Pancreatic Cancer Progression in Mice. First author DOI 10.1016/j.jcmgh.2020.08.011↗
  14. Myeloid Cell Mediated Immune Suppression in Pancreatic Cancer. Co-author DOI 10.1016/j.jcmgh.2021.07.006↗
  15. Apolipoprotein E Promotes Immune Suppression in Pancreatic Cancer through NF-κB-Mediated Production of CXCL1. Co-author DOI 10.1158/0008-5472.can-20-3929↗
  16. Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-3715↗
  17. Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages. Co-author DOI 10.26508/lsa.202000935↗
  18. Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer. Co-author DOI 10.1038/s43018-020-00121-4↗
  19. Macrophage-Released Pyrimidines Inhibit Gemcitabine Therapy in Pancreatic Cancer. Co-author DOI 10.1016/j.cmet.2019.02.001↗

Grants 1

  1. Determining the role of myeloid cells in establishing the pre-metastatic niche in pancreatic cancer F31CA247076↗

Closest collaborators

The 25 strongest of 83 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marina Pasca di Magliano · 12 shared papers, 2019–2025 · strength 1.56
  2. Nina G. Steele · 11 shared papers, 2020–2025 · strength 1.44
  3. Howard C. Crawford · 10 shared papers, 2019–2025 · strength 1.23
  4. Ben Z. Stanger · 5 shared papers, 2023–2025 · strength 0.93
  5. Filip Bednar · 7 shared papers, 2020–2025 · strength 0.86
  6. Eileen S. Carpenter · 7 shared papers, 2020–2025 · strength 0.85
  7. Katelyn L. Donahue · 6 shared papers, 2020–2025 · strength 0.77
  8. Costas Andreas Lyssiotis · 7 shared papers, 2019–2025 · strength 0.73
  9. Zeribe C. Nwosu · 6 shared papers, 2021–2025 · strength 0.72
  10. Timothy L. Frankel · 6 shared papers, 2019–2025 · strength 0.64
  11. Yaqing Zhang · 6 shared papers, 2019–2022 · strength 0.57
  12. Ian M. Loveless · 3 shared papers, 2025 · strength 0.56
  13. Valerie Gunchick · 4 shared papers, 2020–2025 · strength 0.49
  14. Vaibhav Sahai · 4 shared papers, 2020–2025 · strength 0.49
  15. Rosa Elena Menjivar · 3 shared papers, 2021–2025 · strength 0.48
  16. Margo Orlen · 2 shared papers, 2025 · strength 0.44
  17. Jiaqi Shi · 3 shared papers, 2019–2025 · strength 0.39
  18. Benjamin Allen · 3 shared papers, 2020–2025 · strength 0.35
  19. Robert H. Vonderheide · 2 shared papers, 2023–2025 · strength 0.35
  20. Padma Kadiyala · 2 shared papers, 2024–2025 · strength 0.32
  21. Ahmed M. Elhossiny · 2 shared papers, 2024–2025 · strength 0.32
  22. Benjamin Kahn · 2 shared papers, 2023–2024 · strength 0.32
  23. Wenting Du · 2 shared papers, 2024 · strength 0.31
  24. Megan T. Hoffman · 3 shared papers, 2021–2022 · strength 0.30
  25. Daniel James Salas-Escabillas · 2 shared papers, 2021–2025 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.